Status:
WITHDRAWN
Flucelvax Pregnancy Registry
Lead Sponsor:
Seqirus
Conditions:
Pregnant Women, Influenza
Eligibility:
FEMALE
18+ years
Brief Summary
The goal of the registry is to develop a better understanding of the safety of Flucelvax in women and their offspring who were exposed to the vaccine during pregnancy
Eligibility Criteria
Inclusion
- Pregnancy women pregnant women aged 18 years or older within the US who were immunized with the Flucelvax vaccine at any time during pregnancy.The registry will allow eligible pregnant women to selfenroll and also allow HCPs to report de-identified data on pregnancy exposures and outcomes.
- Sufficient evidence to confirm that Flucelvax exposure occurred during pregnancy
- Sufficient information to determine whether the pregnancy is prospectively or retrospectively registered (ie, whether the outcome of pregnancy was known at the time of first contact with the registry)
- Date the pregnancy exposure is registered
- Full reporter (ie, HCP) contact information to allow for follow-up (name, address,etc) The primary population for analysis will include prospectively enrolled pregnancies exposed to Flucelvax that are not lost to follow-up (ie, with outcome information that meet the minimum criteria for evaluation)
Exclusion
- Invalid registry reports and pregnancies deemed lost to follow-up will be excluded from the primary analysis. Retrospective reports will not be included, although retrospective cases with MCMs will be reviewed and reported separately.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02258178
Start Date
September 1 2014
End Date
June 1 2020
Last Update
October 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PPD
Wilmington, North Carolina, United States, 28401